WuXi reveals buyout; UCSF remembers recently deceased biotech pioneer;

@FierceBiotech: Medivation chief amps up rhetoric on Ph3 prostate cancer drug. Story | Follow @FierceBiotech

@RyanMFierce: Bi-specific antibody upstart Oncobiologics charts expansion in new NJ labs. Report | Follow @RyanMFierce

@MaureenFierce: Option-based deals: How biotechs and big pharmas share R&D risks. Article  | Follow @MaureenFierce

> FDA reviewers questioned the benefit of Teva Pharmaceutical Industries' Parkinson's drug Azilect based on trial data on use of the drug to slow progression of the chronic disease. Report

> Oncobiologics, an upstart focused on bi-specific antibodies against cancer immune-related disease, is opening labs in Cranbury, NJ, and plans to double the size of its 25-member staff by the end of next year. Article

> WuXi PharmaTech ($WX), the big China-based CRO, has scooped up research reagents maker Abgent. Financial terms weren't disclosed. Release

> Pharmalot's Ed Silverman outlines how two academics plan to solve the problem of poor disclosure of certain clinical trials data. Item

> Insmed ($INSM) shares took a hit after the company said the FDA has continued a halt of the developer's clinical trial for an inhalable antibiotic called Arikace. Report

> The University of California, San Francisco remembered one of its former faculty members, John Baxter, a biotech pioneer who died earlier this month after a cancer surgery. Item

Pharma News

@FiercePharma: Weak cancer meds, Tamiflu take bite out of Roche sales. Story | Follow @FiercePharma

> Teva wraps Cephalon buy, agrees to sell Provigil copy. News 

> OB/GYN group says KV's Makena deserves reimbursement. Item 

> Will NHS use of Avastin spark a price cut for Lucentis? Report

> NICE on BMS's Yervoy: The cost is too darn high. Story 

And Finally... Reeling from poor sales due the Fukushima nuclear plant disaster near their crops, Japanese rice farmers are setting new safety standards for radiation levels in their grains. Article

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.